Corline Biomedical: Brief Comment on EU Patent
Research Note
2020-07-08
16:23
Redeye has a positive view on the European Patent Office (UPO) intension to approve Corline’s patent application involving the treatment and protection of blood vessels prior to transplantation. Together with the orphan drug designation (ODD), we argue Corline’s heparin technology is well-protected in the European market, importantly mitigating the IP risk. Corline holds the same patent in US and China.
LS
Ludvig Svensson
Disclosures and disclaimers